(Q36747213)

16 August 2017

1 reference

title

The chemoradiation paradigm in head and neck cancer (English)

1 reference

16 August 2017

0 references

Everett E Vokes

1 reference

16 August 2017

Tanguy Y Seiwert

1 reference

16 August 2017

Joseph K Salama

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

156-171

1 reference

Chemotherapy of squamous cell carcinoma of head and neck: the future is now.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

Methotrexate and radiation therapy in the treatment of advanced head and neck tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Management of cancer of the head and neck--a cocktail with your PORT?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

State-of-the-art management of locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0750

1 reference

7 January 2021

Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Measurable impact: multimodality therapy of head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

The concurrent chemoradiation paradigm--general principles

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Presurgical cytoreduction of oral cancer using intra-arterial cisplatin and limited concomitant radiation therapy (Neo-RADPLAT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Chemotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Mitomycin lung toxicity. Acute and chronic phases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

A prospective study of pulmonary function in patients receiving mitomycin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Intensity-modulated radiation therapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0750

7 January 2021

Identifiers

DOI

10.1038/NCPONC0750

1 reference

16 August 2017

1 reference